Summary Several unique features of neuroblastoma (NB), including the capacity for spontaneous regression and maturation to benign pathology, suggest that genes that regulate cellular proliferation, survival and differentiation may be involved in directing clinical tumour aggressiveness. The in situ expression of Bcl-2, Rb, p21, p53 and Bax proteins, as well as the proliferation marker proliferating cell nuclear antigen (PCNA) were examined immunocytochemically in a selection of 38 stage-and outcome-identified NB tumours. Apoptotic cells were identified morphologically and by a DNA fragmentation labelling technique (TUNEL). Although the tumour cell density of Bcl-2, p53, Bax, PCNA and TUNEL positivity correlated with patient survival, a spatially organized expression pattern was further recognized in stroma-poor differentiating tumours. Immature tumour cells adjacent to thin fibrovascular stroma are proliferating, as evidenced by PCNA positivity, and often express Bcl-2. At increasing distance from this fibrovascular stroma, intermediately differentiated tumour cells express Rb, while with more advanced differentiation, proliferation ceases and Bcl-2 immunoreactivity is lost. The most differentiated tumour cells, which often express p53, and occasionally p21 and Bax, lie adjacent to TUNEL-positive, morphologically apoptotic cells. This spatial organization in favourable outcome NB tumours suggests that physiological regulation of differentiation and apoptosis may be involved in tumour regression.
Neuroblastoma (NB) is an embryonal malignancy of infancy and childhood that may originate at any site at which sympathetic nervous system (SNS) tissue is located. The prognosis of patients with NB is highly dependent upon patient age at diagnosis and clinical tumour stage; younger patients with lesser tumour burden enjoying the most favourable prognosis (Evans et al, 1971; Shimada et al, 1984) . Several unique features of NB suggest that the molecular events controlling cellular proliferation, growth arrest, differentiation and particularly cellular death may be involved in dictating clinical aggressiveness. For instance: (1) spontaneous regression of a predominantly infantile subgroup of highly metastatic tumours, referred to as IVS, occurs more frequently in NB than in any other tumour (D'Angio et al, 1971; Evans et al, 1976a; Everson and Cole, 1966) ; (2) NB in situ, the finding of neuroblastic tumours in adrenal glands obtained from non-afflicted infants at autopsy, indicates a high incidence of unrecognized spontaneous resolution (Beckwith and Martin, 1968; Beckwith and Perrin, 1962) ; (3) advanced morphological tumour cell differentiation correlates with favourable patient outcome (Shimada et al, 1984) ; and (4) spontaneous tumour maturation of malignant NB tumours to that of benign pathology, i.e. ganglioneuroma, is recognized (Evans et al, 1976b; Nitschke et al, 1988) . Our previous work suggests that the extent of apoptosis and proliferation, and the phenotypic mode of tumour cellular differentiation, may be helpful in explaining tumour biology (Gestblom et al, 1995; Hedborg et al, 1995a;  Revised 8 October 1996 Accepted 23 October 1996 Correspondence to: S P&hlman, Department of Medicine, Wallenberg Laboratory, Lund University, University Hospital MAS, S-205 02 Malmo, Sweden Hoehner et al, 1995a, b) . These characteristics lead us to hypothesize that the disparity in clinical behaviour of different forms of NB may involve differences in the regulation of apoptosis-related genes.
Several genes that dictate cellular decisions regarding proliferation, growth arrest and cellular death have been identified. p53 is a tumour-suppressor gene (Dowell and Hall, 1994) , the protein product of which normally suppresses tumour formation by promoting the transcription of genes that inhibit uncontrolled proliferation. p53 appears to control a critical cell cycle checkpoint reponsible for maintaining genomic integrity by inducing growth arrest and subsequent DNA repair in GI of the cell cycle following sublethal DNA damage (Kastan et al, 1991) . p53 functions biochemically as a sequence-specific DNA-binding transcription factor (Zambetti et al, 1992; Cho et al, 1994) and induces downstream genes resulting in cellular death in some cell types (YonishRouach et al, 1991; Shaw et al, 1992; Lane, 1993) . Homozygous alterations in p53, resulting in a non-functional protein, are the most frequently identified genetic aberrations identified in solid tumours (Greenblatt et al, 1994) ; but this appears not to be true for NB (Davidoff et al, 1992; Imamura et al, 1993; Vogan et al, 1993; Hosoi et al, 1994) . The accumulation of p53 in neoplastic cells appears to be critically dependent upon influences from the cellular environment (Voijtesek and Lane, 1993; Lane, 1994) , apart from simply reflecting the protein's intrinsic structure and stability (Hall and Lane, 1994) .
The retinoblastoma (Rb) tumour-suppressor gene product restricts cell cycle progression at G,/S by virtue of its ability to inhibit transcription factors, and may also play a role in apoptosis inhibition, as proteins that inhibit Rb function also induce apoptosis. (Rao et al, 1992; White et al, 1994; White, 1994 , 1995) . Relationships between Rb and p53 in cell cycle regulaFunctional interactions between the p53 and the gene products tion may be suggested based on the action of other proteins reguof the bcl-2 gene family may also exist (Cory et al, 1994) . The lated by p53. p21 (also referred to as Cipi, WAFI and Sdil), which bcl-2 gene product is recognized to maintain or prolong cellular is transcriptionally induced by p53, thereafter inactivates other survival in a variety of situations (Garcia et al, 1992; Altsopp et al, factors required for cell cycle progression (Harper et al, 1993) . In 1993; Reed, 1994) , further evidence indicated by the extensive and the absence of p21, these other factors complex with cyclins to inappropriate apoptotic cell death in homozygous genetic deletion phosphorylate Rb, the under-phosphorylated form exerting a negaanimals (Veis et al, 1993) . A number of Bcl-2 complexing homotive regulatory effect on gene expression by complex formation logues, including Bax, have also been identified. While Bcl-2 with other DNA-binding proteins (Buchkovich et al, 1989; Chen et homodimers promote cell survival, progressive concentrational, 1989 ). Thus, Rb may function by sequestering other cellular dependent transition to Bax homodimers has been suggested to proteins with growth-promoting activities. Both Rb and p53 are promote cell death (Oltval et al, 1993) . p53 may regulate the relainvolved in cell cycle regulation, Rb apparently being essential for tive stoichiometry of these proteins by inducing decreases in exit from the cell cycle, whereas p53 activation can inhibit cell
Bcl-2 and increases in Bax Selvakumaran cycle progression (Cordon-Cardo, 1995 .
In this investigation, we examine the cellular expression of these cell cycle checkpoint genes in a well-documented group of clinical NB tumours. We concurrently examine cellular proliferation, differentiation and apoptosis in relation to the expression of these gene products. The spatial organization of the expression patterns obtained will be discussed in relation to tumour architecture.
MATERIALS AND METHODS Tumour materials
A total of 38 infants and children with NB, ganglioneuroma (GN) or ganglioneuroblastoma (GNB) were identified from a populationbased, consecutive inquiry of all medical centres in Sweden that provide surgical treatment of the disease. Adequate clinical data, follow-up and sufficient histological materials were criteria for study inclusion. Biopsy or resection specimens of primary, and in some instances metastatic, tumours were evaluated. Tumour stage was determined clinically at the time of surgical biopsy or resection in accordance with INSS criteria . Patients were at varying stages of treatment at the time of tissue acquisition; the majority of patients with stage 3 and 4 disease received cytotoxic therapy before the time of tumor biopsy or resection (60%), whereas those with stage 1, 2, 4S, GN or GNB had not (0%). Patient characteristics are summarized in Table 1 . At a median follow-up of 56 months, all nine patients with Stage 1, stage 2a and 2b disease are alive and free of disease. Of children with stage 3 disease, four out of nine (44%) have died, whereas 8/11 (73%) of children with stage 4 tumours have succumbed to progressive disease. N-myc amplification of greater than tenfold was associated with 100% mortality (6/6). All tumours were histologically graded with respect to stroma content, extent of differentiation and mitosis-karyorrhexis index, in accordance with previously reported criteria (Shimada et al, 1984) . Statistical comparisons of outcome with other prognostic features in this group of patients have previously been reported (Hedborg et al, 1995b ).
Tissue preparation and immunohistochemistry
Tumour samples were fixed in 4% buffered formaldehyde, embedded in paraffin and sections of 4-5 ,um were secured to glass pretreated with silane and acetone. Deparaffinization was performed by baking slides ovemight at 370C, and transfer through xylene and progressive dilutions of ethanol to deionized distilled water (DDW).
Deparaffinized tissue sections were subjected to microwave treatment in 10 mm sodium citrate buffer, pH 7.3, for 15 min at 750 W. Tissue sections were washed in DDW and blocked with 2% bovine serum albumin (BSA) in Tris-HCl buffered saline buffer for 20 min. Primary antibody at optimal dilution was added to sections with incubation from 1 h to overnight at either room temperature (RT) or 4°C respectively. Slides were rinsed and then incubated for 30 min at RT with either appropriate alkaline phosphatase-conjugated or biotin-conjugated secondary antibody at 1:40 dilution (Sigma Chemical Co., St Louis, MO, USA). Sections were again rinsed and developed using Fast-red-TR-salt or 3-amino-9-ethylcarbazole (both Sigma) as chromogen. Slides were rinsed in tap water, some sections counterstained with haematoxylin, and mounted. Negative controls were obtained by exclusion of primary or secondary antisera, and primary antiserum replacement with species-appropriate non-immune antisera (Sigma) at equivalent concentrations.
The primary antibodies used in this study and their documented characterization and/or previous employment are as follows: monoclonal anti-Bcl-2 antibody (MAB 124; Dakopatts, Glostrup, Denmark) (Pezzella et al, 1990; Hockenbery et al, 1991) at 1:100 dilution, monoclonal anti-neuron-specific enolase (NSE) antibody (Dako-NSE, H14; Dakopatts) at 1:50 dilution, monoclonal anti-tyrosine hydroxylase (TH) antibody (Rohrer et al, 1986; Hoehner et al, 1995a ) (Boehringer Mannheim, Germany) at 1:75 dilution, monoclonal anti-PCNA antibody (Kurki et al, 1988; Hall et al, 1990; Gestblom et al, 1995) (Boehringer Mannheim) at 1:50 dilution, monoclonal anti-p53 antibody (DO-7; Dakopatts) (Jacquemier et al, 1994; Nylander et al, 1995) at 1:200 dilution, monoclonal anti-p53 antibody (Ab-2; Oncogene Science, Uniondale, NY, USA) (Jacquemier et al, 1994) DNA nick end-labelling of tissue sections A procedure specifically to end label DNA cleavage sites in tissue sections in situ (TUNEL) was employed as previously described with minor modifications (Gavrieli et al, 1992; Hoehner et al, 1995b) . Tumour sections were deparaffinized and incubated in a moist chamber for 15 min with 20 jig ml-1 proteinase K (Sigma). Hydrogen peroxide (2%) was added for 5 min to inactivate endogenous peroxidase, followed by incubation at 370C for 60 min with terminal deoxynucleotidyl transferase (10 eu 50 l-1) and biotinylated deoxyuridine (dUTP; 0.5 nmol 50 j1-1) ( We have previously reported the existence of 'tumour lobule' architecture in selected differentiating histology tumours Hoehner et al, 1995a) , an arrangement by which a continuum of neuroendocrine tumour cell differentiation can be more easily identified (Figure 1 ). In these tumours, TH immunoreactivity was least evident in tumour cells adjacent to the thin fibrovascular stroma (Figure 2A and B), these tumour cells typically possessing dense nuclei and scant cytoplasm, reflecting lesser cellular differentiation. TH expression progressively increased in morphologically more differentiated tumour cells nearing the centre of the lobule structure. Findings with NSE were similar, intense positivity clearly identifying tumour cells with more differentiated morphological characteristics identified by their abundant cytoplasm ( Figure 2C ). Of the 14 tumours with this 'tumour lobule' arrangement of cells, all show differentiating histology, all but one were discovered in patients less than 13 months of age, and 12/14 enjoyed favourable outcome at extended follow-up (Table) .
Of the two non-survivors, one death was the result of haemodynamic neuroendocrine crisis rather than tumour progression, and the other patient with neonatal 4S disease succumbed secondary to massive tumour volume causing severe respiratory distress.
Proliferating cell (PCNA) immunocytochemistry
Proliferating cell nuclear antigen (PCNA) immunoreactivity was exclusively nuclear, positive cells often displaying morphological evidence of mitotic activity, but more often morphologically nonmitotic in appearance. Positive controls, including the basal germinal layer of the epidermus, basal intestinal epithelial crypt cells and fetal adrenal cortex, confirmed PCNA positivity in those tissues known to have high proliferative rates (not shown). In NB tumours, the cellular density of PCNA-positive tumour cells correlated with unfavourable patient outcome (Figure 1 ) (Gestblom et al, 1995) . The majority of undifferentiated tumours displayed PCNA positivity in a randomly scattered pattern; however, in differentiating tumours with lobule architecture, the greatest density of reactive tumour cells was located adjacent to thin fibrovascular stroma and capillaries ( Figure 2E ). In tumour regions more distant from this vascular supply, PCNA-positive cells became less frequent.
Apoptosis-related gene expression
Nuclear-specific p21 immunoreactivity was identified in all tumours examined; however, p21-reactive cells were scattered and sparse, with a cellular density never exceeding 5% of the total tumour cell number (not shown interspersed with other morphologically highly differentiated tumour cells ( Figure 2G ).
Bcl-2 immunoreactivity was identified in all tumours examined. Reactivity was exclusively cytoplasmic, and positive controls, including lymphocyte aggregates, sympathetic ganglia and intestinal epithelia, were in accordance with previously reported immunoreactivity results (Hockenbery et al, 1991; LeBrun et al, 1993; Hoehner et al, 1995a) . Positivity was localized to tumour cells proper and absent from cells comprising the fibrovascular tumour stroma. In differentiating tumours, the morphologically most differentiated tumour cells were frequently Bcl-2 non-reactive, whereas morphologically immature or intermediately differentiated tumour cells possessed Bcl-2 positivity ( Figure 2D ). The majority of cells in the homogeneous and morphologically immature tumour cells of undifferentiated tumours were typically Bcl-2 negative, as reflected by the significantly lower density of cellular positivity (Figure 1) .
Rb immunoreactivity, specifically localized to the nucleus, was identified in a large proportion of tumour cells, approximating the pattern of immunoreactivity observed with PCNA immunocytochemistry. Adjacent Tumour cell p53 immunoreactivity was observed in all NB tumours examined. Reactivity was nuclear restricted, and neither cytoplasmic p53 immunoreactivity nor non-neoplastic cellular positivity was appreciated. Both anti-p53 antisera used in this investigation gave equivalent and consistent results. The majority of tumours exhibited scattered p53 cellular staining, ranging from a very sparse cellular density positivity to 80% of cells displaying immunocytochemically detectable p53 protein (Table) . Comparisons of the density of p53-positive tumour cells (antiserum DO-7) with patient outcome confirms the significantly higher density of p53-positive tumour cells in tumours from patients with unfavourable outcome vs long-term survivors (Figure 1 ), in accordance with previous reports (Davidoff et al, 1992) . Furthermore, in tumours which exhibit evidence of heterogeneous morphological tumour cell differentiation and lobule architecture, p53 protein was most frequently detected in the most differentiated cells located distant from tumour fibrovascular stroma, and immediately adjacent to tumour cells with morphological characteristics of apoptosis ( Figure 2F ). p53 was typically absent from tumour cells lying close to the fibrovascular tumour stroma with morphologically lessdifferentiated characteristics.
Bax immunoreactivity was not detectable in a number of the NB tumours studied. Only large differentiated cells of GN tumours and the most differentiated cells of some differentiating NB tumours, often arranged in pseudorosettes, revealed Bax immunoreactivity ( Figure 2H ). Immunoreactivity was restricted to the cytoplasm of these cells. Bax immunoreactivity was particularly absent in tumours lacking evidence of morphological differentiation. Positivity was confirmed in differentiated neurons of dorsal root ganglia, spinal cord and sympathetic ganglia of normal human fetal and post-natal specimens, in accordance with previous reports Miyashita et al, 1994) (not shown).
Apoptosis detection
TUNEL staining, which identifies DNA fragmentation in situ, was identified in all tumours examined, the cellular density of which is depicted in the Table. Statistical correlations confirm the previously reported relation between TUNEL positivity and favourable patient outcome (Figure 1) (Gestblom et al, 1995; Hoehner et al, 1995a) . Positivity was exclusively nuclear, the morphology of positive cells often suggestive of apoptosis, with condensed, pyknotic and often fragmented nuclei. TUNEL-positive cells were often randomly scattered in tumours, but were also occasionally identified in groups. In differentiating tumours, TUNEL-positive cells were most abundant in tumour regions distant from the fibrovascular stroma bordering the morphologically most differentiated tumour cells ( Figure 2E ).
DISCUSSION Architectural arrangement of solid tumour growth
The spatial arrangement of angiogenesis, tumour cell proliferation and cellular death in other solid tumour models sheds light upon the molecular events that we report. Solid tumour growth is highly dependent upon vascular acquisition (Folkman, 1990) . Tumours grown in isolated perfused organs in which vessels fail to proliferate are limited to 1-2 mm3 in size (Folkman et al, 1966) , as are tumours that remain viable but avascular under experimental conditions in vivo (Gimbrone et al, 1974) . With induction of angiogenesis and vascular incorporation, tumour growth occurs predominantly along these newly formed vessels, the density of which is higher at the tumour periphery than at the centre (Thompson et al, 1987) . Tumour cell proliferation also diminishes with increasing distance from the nearest capillary (Tannock, 1970) . The topography and mode of cellular death in tumours is determined largely by the rate of tumour cell proliferation relative to the process of angiogenesis, but is also critically dependent upon intrinsic tumour cell properties (Arends et al, 1994) . Locally expanding tumours may produce hypoxia-induced necrotic zones, observed at a strikingly constant distance from blood vessels both in vitro and in vivo (Tannock, 1968; Franko and Sutherland, 1979 (Arends et al, 1994 (Kerr et al, 1972; Wyllie et al, 1980) . They often lie clustered a strikingly constant distance from their nearest vascular support, typically 150-300 gm, occasionally bordering neuropil, necrosis and/or calcifications (not shown).
Organization of undifferentiated NB tumours
All NB tumours in this investigation that proved fatal as a result of tumour progression failed to possess the tumour lobule characteristics described above. Patterns of immunoreactivity and TUNEL positivity in these tumours were randomly scattered, and neither consistent morphological tumour cell differentiation nor a welldeveloped/organized fibrovascular stroma was readily appreciated. Although quantitative findings indicate that unfavourable outcome tumours possess a lower proportion of Bcl-2-positive tumour cells, this varies among reports (Castle et al, 1993; Ramani and Lu, 1994; Hoehner et al, 1995a; Ikegaki et al, 1995; Krajewski et al, 1995) . Undifferentiated and/or unfavourable outcome NB tumours often accumulate p53 protein; results in agreement with others (Davidoff et al, 1992; Moll et al, 1995) . Fatally progressive tumours also possess a higher rate of proliferation and a lower percentage of apoptotic cells, consistent with other reports (Gestblom et al, 1995; Hoehner et al, 1995a) and with results obtained in defined solid tumour systems (Arends et al, 1994) . The finding that Rb is quantitively homogeneous among clinical NB tumours is in keeping with the findings that Rb protein expression is relatively high in a number of NB cell lines (Ikegaki et al, 1991 (Ikegaki et al, , 1994 and exists in normal maturing tissues, both proliferating and non-proliferating (Cordon-Cardo and Richon, 1994) .
In situ association of tumour architecture, proliferation, cellular death and apoptosis-related gene expression
To explain these prognostic, cellular architectural and cellular gene expression findings, we conclude that at least two principally disparate forms of NB tumours exist. One form in which genetic aberrations cause severe disruption in the normal control of cell cycle checkpoint gene regulation and differentiation, i.e. prognostically unfavourable tumours; and a second form in which the genetic impetus for the malignant phenotype does not severely impede these processess and molecular events proceed as expected in lieu of the tumour architectural limitations. From a genetic, biological, histological and clinical sense, this view of distinctly disparate NB tumour types has factual support (Brodeur, 1995; Hedborg et al, 1995b) . One tumour form frequently harbours amplification of the N-myc gene, has undifferentiated histology, is diffuse and/or metastatic, occurs in older children, and is most often fatally progressive; and another form possesses a normal N-myc copy number, differentiating histology, localized growth, and is discovered in younger children who typically survive their disease.
In biologically and clinically unfavourable tumours, tumour organization is typically poorly structured. Although this creates difficulties in spatially defining cell cycle regulatory gene expression patterns, quantitative findings suggest that inappropriate regulation exists, i.e. elevated p53 and low Bcl-2, with high proliferation. In contrast, many NB tumours with favourable prognostic features appear to possess relatively physiological expression of these genes (Figure 3 ). In these tumours, Bcl 2 is intensely expressed by those immature tumour cells that lie adjacent to the fibrovascular stroma, and is down-regulated as proliferation causes more centralized displacement of these tumour cells. As cellular differentiation occurs, tumour cells die by apoptosis at a relatively constant distance from the nearest vascular supply. Down-regulation of Bcl-2 in this situation would be predicted not only by similar findings in fetal sympathetic nervous system cells that choose an adrenal or extra-adrenal chromaffin differentiation lineage Krajewski et al, 1995) , but also by cells whose death is defined as apoptotic (Hockenbery et al, 1991; Greenlund et al, 1995) . Although Bcl-2 is best characterized as a gene that protects against cell death, another view is that these Bcl-2-positive tumours are 'primed' or British Journal of Cancer (1997) (Hockenbery et al, 1991 ; however, expression patterns, which would help verify that Bax counteracts the survival effects of Bcl-2 (Oltval et al, 1993) and thus potentiates apoptosis, were not frequently observed even in NB tumours characterized by more extensive apoptotic cell death. The finding that clusters of p53-positive cells lie just adjacent to tumour regions rich with apoptosis fits well with its determined function. p53 is normally up-regulated by toxic agents, UV irradiation or hypoxia, this believed to allow time for enacting DNA repair (Maltzman and Czyzyk, 1984; Hall et al, 1993; Lu and Lane, 1993) . Although clinical tumour studies have confirmed genetic point mutations as a frequent cause of p53 accumulation (Greenblatt et al, 1994) , environmental conditions may also influence protein stability or gene transcription and therefore alter the cellular content of p53 protein (Lane, 1993; Hall and Lane, 1994) . In 'lobular' NB tumours, p53 is specifically localized to tumour cells that lie some 15-25 cell diameters from their most immediate blood supply. At this location, tumour cells no longer proliferate, they have lost or down-regulated their survival gene bcl-2, and they up-regulate the expression of p53, presumably to attempt damage repair in a region compromised of blood-borne metabolites. If this is unsuccessful, apoptosis would occur. Therefore, p53 regulation in these tumours might be physiological, and is activated/expressed in those cells in which cellular insults have occurred as they acquire distance from their metabolic vascular supply. Although cellular expression of p21 was typically sparsely scattered in these tumours, p21 was occasionally localized to the same group of tumour cells that harboured p53 positivity. As p21 is known to function downstream of p53 (el-Deiry et al, 1993) , cellular co-expression of these two molecules may represent activation of a common pathway directed towards cellular repair and/or apoptosis. Rb protein was localized to maturing cells either proliferating or non-proliferating in accordance with other reports (Cordon-Cardo and Richon, 1994 ). It appears to be absent from the most differentiated tumour cells, as well as from those cells actively undergoing apoptosis.
Implications
A subset of clinical NB tumours has been identified in which cell cycle checkpoint and apoptosis-related gene expression appear spatially and potentially physiologically linked in situ (Figure 3 ).
The arrangement of cells in these tumours reflects ongoing angiogenesis, proliferation, necrosis and apoptosis, in part analogous to the spatial relationships described in other experimental tumour systems. Therefore, NB may represent a particularly relevant system, both clinically and physiologically, for examining the normal in vivo regulation of these genes. Interestingly, this cellular organization is identified primarily in a subset of tumours with favourable biological characteristics, tumours that may also possess regressive tendencies. Although blood-borne oxygen, metabolites or growth factors, such as neurotrophins (Hoehner et al, 1995b) , could be involved in directing the observed molecular and histological events, other microenvironmental, endothelial/stromal-derived or adjacent tumour cell paracrine interactions could also be indicated. An interesting observation is that concurrent with this molecular cascade of events, morphological differentiation of tumour cells also occurs. Nonetheless, this architectural arrangement suggests that exogenous or diffusable factors may possess significant control over tumour growth, cellular differentiation and programmed cell death in some tumours, whereas other tumours may be relatively refractory to these influences, possibly a reflection of their intrinsic genetic mutations.
